Which antibiotics increase risk of sudden death in your patient on haemodialysis? Probably something you should know. Check out our rapid-fire summary tweetorial at the link!
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
Which antibiotics increase risk of sudden death in your patient on haemodialysis? Probably something you should know. Check out our rapid-fire summary tweetorial at the link!
⚖️As doctors we guide our practice by the principle: primum, non nocere
— Nephrology Jrnl Club (@NephJC) July 22, 2022
⁉️ Premise: pt on hemodialysis develops pneumonia. What antibiotic would you use?
Welcome to #TenTweetNephJC
✳️ 10 tweets #NephJC catch-up ✳️ pic.twitter.com/PHeR0c7EkV